Welcome to our dedicated page for CONMED Corporation news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on CONMED Corporation stock.
CONMED Corporation (symbol: CNMD) is a global leader in medical technology, specializing in the development and sale of innovative surgical and patient monitoring products. Headquartered in Utica, New York, CONMED employs approximately 3,500 individuals who are dedicated to improving healthcare quality through high-quality product design, production, and marketing.
The company's core business encompasses a diverse range of specialties, including orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. These products are known for their technological advancements, enabling physicians to deliver superior care and achieve enhanced clinical outcomes for their patients.
CONMED operates through two primary reporting units: Orthopedic Surgery and General Surgery. Geographically, the company is U.S.-centric, with the majority of its revenue generated domestically. The EMEA region contributes the second-largest revenue share, followed by APAC and the non-U.S. Americas.
The company's recent achievements include advancements in their surgical products and technology, which continue to set industry standards. Current projects are focused on enhancing product efficiency and expanding their global reach through strategic partnerships and innovations.
CONMED's mission centers around improving healthcare quality. Each employee is committed to customer satisfaction and enhanced patient outcomes, reflecting the company's core values. They strive to exhibit thoughtful leadership, provide meaningful opportunities for employees, and act as a responsible corporate citizen in the communities where they operate.
Recent news highlights include ongoing developments in their product lines and strategic initiatives to bolster market presence. With a strong financial foundation and continuous innovation, CONMED remains a pivotal player in the medical technology sector.
CONMED Corporation (NYSE: CNMD) announced participation of Curt R. Hartman, Chair of the Board and CEO, alongside Todd W. Garner, CFO, in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference. The event is scheduled for 9:20 a.m. ET on February 25, 2021.
The live webcast will be available in the ‘Investors’ section of their website, and a replay will be accessible post-event. CONMED is a provider of surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.
CONMED Corporation (NYSE: CNMD) reported Q4 2020 sales of $252.8 million, down 4.5% year-over-year, with domestic revenue decreasing 0.7% and international revenue falling 9.1%. Diluted EPS rose to $0.81 from $0.49 in Q4 2019, while adjusted EPS decreased from $0.90 to $0.84. For the full year, sales were $862.5 million, a 9.7% decline, and diluted EPS was $0.32 versus $0.97 in 2019. The company expects 2021 revenue between $975 million and $1.02 billion, with adjusted EPS forecasted at $2.85 to $3.05.
CONMED Corporation (CNMD) will report its fourth quarter and full year 2020 financial results on January 27, 2021, post-market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Participants can join the call by dialing specific numbers provided or via a webcast accessible through the company’s website. A recording of the call will be available for one week following the event. The company specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) announces that Curt R. Hartman and Todd W. Garner will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2021, at 10:00 a.m. ET. The presentation will be accessible via a live webcast on the Company's website at www.conmed.com, with a replay available post-event. CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.
CONMED Corporation (NYSE: CNMD) announced participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. CEO Curt R. Hartman and CFO Todd W. Garner will feature in a pre-recorded fireside chat, available from 10:00 a.m. ET on November 23 until December 3, 2020. Interested parties can access the chat through the conference site or via the Company’s website. CONMED specializes in surgical devices for minimally invasive procedures across various specialties including orthopedics and neurosurgery.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, scheduled for payment on January 5, 2021, to shareholders of record as of December 15, 2020. This dividend reflects the company's commitment to returning value to its shareholders. As a medical technology company, CONMED offers surgical devices for various medical specialties including orthopedics, general surgery, and more. The announcement signals confidence in the company's ongoing financial health and operational stability.
CONMED Corporation (NYSE: CNMD) announced a change in its presentation time at the Jefferies Virtual London Healthcare Conference to 11:25 a.m. ET on November 18, 2020. Todd W. Garner, Executive Vice President and CFO, will represent the company. The presentation will be available via a live webcast on the company's website, with a replay accessible afterward.
CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties, including orthopedics, general surgery, and more. For further details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) announced that Todd W. Garner, Executive Vice President and CFO, will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:25 p.m. ET. A live webcast of the presentation will be available in the ‘Investors’ section on the company’s website, with a replay accessible post-event. CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties including orthopedics and neurosurgery. For further details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) reported Q3 2020 financial results with sales of $237.8 million, an increase of 1.8% year-over-year. Domestic revenues grew by 4.7%, while international revenues fell by 1.7%. GAAP diluted EPS was $0.23, unchanged from Q3 2019, but adjusted diluted EPS rose to $0.88 from $0.62. The company noted ongoing operational challenges due to COVID-19 but expressed confidence in achieving future growth. However, financial guidance remains unavailable due to pandemic uncertainties.
CONMED Corporation (NYSE: CNMD) will report its financial results for Q3 2020 after market close on October 28, 2020. A conference call will be held at 4:30 p.m. ET for discussions regarding the results. Interested parties can access the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) using passcode 2498889. The call will also be webcast on the company’s website. Forward-looking statements will be included, highlighting potential risks and uncertainties affecting future performance.
FAQ
What is the current stock price of CONMED Corporation (CNMD)?
What is the market cap of CONMED Corporation (CNMD)?
What does CONMED Corporation specialize in?
Where is CONMED Corporation headquartered?
How many employees does CONMED Corporation have?
What are the main product specialties of CONMED Corporation?
What are the primary reporting units of CONMED Corporation?
In which regions does CONMED Corporation generate most of its revenue?
What is the mission of CONMED Corporation?
How does CONMED Corporation ensure customer and patient satisfaction?
What recent achievements has CONMED Corporation made?
What is CONMED Corporation's approach to innovation?
